Gotch, you are right about the number of shares on issue - it is about 97m. Your estimate of profit margin at 30%, I suspect, could be on the low side. Costs appear to have plateaued around the $4m per quarter level, and analysis of recent quarterly figures suggests margins may be 60%+ for revenue in excess of that (cost) level. When revenue is in the $100m zone, such figures will be lost in the blur.
That means that we can project pre-tax earnings of $80m+ when revenues reach the $160m which looks likely in three years time. That yields after-tax earnings of around $56m, or about 58c per share. Picking an appropriate PER is still a guessing game, but most successful, rapidly-growing biotechs seem to be able to justify a PER of at least 25, some much higher. What do you think is reasonable?
Cheers, Prime
- Forums
- ASX - By Stock
- rising revenue and wide moats
CST
castile resources ltd
Add to My Watchlist
0.00%
!
6.0¢

Gotch, you are right about the number of shares on issue - it is...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
6.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $18.34M |
Open | High | Low | Value | Volume |
6.0¢ | 6.0¢ | 6.0¢ | $2.913K | 48.55K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 449683 | 6.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.2¢ | 94279 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 449683 | 0.060 |
1 | 100000 | 0.059 |
2 | 130000 | 0.058 |
2 | 74000 | 0.057 |
2 | 217857 | 0.056 |
Price($) | Vol. | No. |
---|---|---|
0.062 | 94279 | 1 |
0.063 | 54563 | 1 |
0.065 | 200000 | 1 |
0.069 | 217154 | 2 |
0.070 | 400000 | 2 |
Last trade - 09.59am 31/07/2025 (20 minute delay) ? |
Featured News
CST (ASX) Chart |